Protein Summary
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation. The product of this gene belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is involved in platelet aggregation, and is a potential target for the treatment of thromboembolisms and other clotting disorders. Mutations in this gene are implicated in bleeding disorder, platelet type 8 (BDPLT8). Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jul 2013]
- ENST00000302632
- ENSP00000307259
- ENSG00000169313
- HORK3
- HORK3
- P2Y12
- ADPG-R
- BDPLT8
- SP1999
- P2T(AC)
- P2Y(AC)
- P2Y(12)R
- P2Y(ADP)
- P2Y(cyc)
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological term | 0.91 | ||
ligand (chemical) | 0.76 | ||
biological process | 0.69 | ||
cell type or tissue | 0.65 | ||
tissue sample | 0.59 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 3933.58 (req: < 5)
Gene RIFs: 201 (req: <= 3)
Antibodies: 178 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 3933.58 (req: >= 5)
Gene RIFs: 201 (req: > 3)
Antibodies: 178 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 34
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 677
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 5